Agonist monoclonal antibodies (mAbs) are a class of immunomodulatory agents which activate co-stimulatory receptors on immune cells, leading to activation, proliferation, and enhanced effector function. These therapies have led to robust responses in preclinical models. However, systemic administration of agonist mAbs has been plagued by potentially fatal dose limiting toxicities, including cytokine release syndrome (CRS). Additionally, systemic overstimulation of the immune system risks the development of autoimmune disorders. With that in mind, my project will explore the efficacy of locally administered agonist mAbs, achieving durable anti-tumor responses while avoiding the adverse effects associated with systemic delivery.
|K. Dane Wittrup, Ph.D.
C. P. Dubbs Professor of Chemical Engineering and Bioengineering
Associate Director, Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
500 Main Street,
Cambridge, MA 02139
Office Phone: 617-253-4578
Department of Chemical Engineering
Department of Biological Engineering
Koch Institute for Integrative Cancer Research